Nebulization of Vancomycin Provides Higher Lung Tissue Concentrations than Intravenous Administration in Ventilated Female Piglets with Healthy Lungs

Background: Intravenous vancomycin is used to treat ventilator-associated pneumonia caused by methicillin-resistant Staphylococcus aureus, but achieves high rates of failure. Vancomycin nebulization may be efficient to provide high vancomycin lung tissue concentrations. The aim of this study was to compare lung tissue and serum concentrations of vancomycin administered intravenously and by aerosol in mechanically ventilated and anesthetized healthy piglets. Methods: Twelve female piglets received a single intravenous dose of vancomycin (15 mg/kg) and were killed 1 (n = 6) or 12 h (n = 6) after the end of administration. Twelve piglets received a single nebulized dose of vancomycin (37.5 mg/kg) and were killed 1 (n = 6) or 12 h (n = 6) after the end of the aerosol administration. In each group, vancomycin lung tissue concentrations were assessed on postmortem lung specimens using high-performance liquid chromatography. Blood samples were collected for serum vancomycin concentration measurement 30 min and 1, 2, 4, 6, 8, and 12 h after the end of vancomycin administration. Pharmacokinetics was analyzed by nonlinear mixed effect modeling. Results: One hour after vancomycin administration, lung tissue concentrations in the aerosol group were 13 times the concentrations in the intravenous group (median and interquartile range: 161 [71, 301] μg/g versus 12 [4, 42] μg/g; P < 0.0001). Twelve hours after vancomycin administration, lung tissue concentrations in the aerosol group were 63 (23, 119) μg/g and 0 (0, 19) μg/g in the intravenous group (P < 0.0001). A two-compartment weight-scaled allometric model with first-order absorption and elimination best fit serum pharmacokinetics after both routes of administration. Area under the time-concentration curve from 0 to 12 h was lower in the aerosol group in comparison to the intravenous group (56 [8, 70] mg · h · l−1 vs. 121 [103, 149] mg · h · l−1, P = 0.002). Using a population model, vancomycin bioavailability was 13% (95% CI, 6 to 69; coefficient of variation = 85%) and absorption rate was slow (absorption half life = 0.3 h). Conclusions: Administration of vancomycin by nebulization resulted in higher lung tissue concentrations than the intravenous route. The hypothesis that lung tissue vancomycin concentrations will be higher after administration as an inhaled aerosol than after intravenous administration was tested in healthy, anesthetized, mechanically ventilated female piglets. One hour after administration of a 37.5 mg/kg aerosol dose, the median lung tissue vancomycin concentration (161 µg/g) was 13 times that after intravenous administration of 15 mg/kg (12 µg/g). Twelve hours after aerosol administration, the median lung tissue vancomycin concentration was 63 µg/g, while 12 h after intravenous administration, vancomycin was undetectable in 60% of lung specimens. Supplemental Digital Content is available in the text.

[1]  S. Harbarth,et al.  Methicillin-resistant Staphylococcus aureus , 2018, Nature Reviews Disease Primers.

[2]  Zhongheng Zhang,et al.  Nebulization of antimicrobial agents in mechanically ventilated adults in 2017: an international cross-sectional survey , 2018, European Journal of Clinical Microbiology & Infectious Diseases.

[3]  J. Rello,et al.  Nosocomial pneumonia in 27 ICUs in Europe: perspectives from the EU-VAP/CAP study , 2016, European Journal of Clinical Microbiology & Infectious Diseases.

[4]  J. Riera,et al.  Key considerations on nebulization of antimicrobial agents to mechanically ventilated patients. , 2017, Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases.

[5]  J. Farber,et al.  The Nephrotoxicity of Vancomycin , 2017, Clinical pharmacology and therapeutics.

[6]  J. Riera,et al.  Nebulization of Antiinfective Agents in Invasively Mechanically Ventilated Adults: A Systematic Review and Meta-analysis , 2017, Anesthesiology.

[7]  F. Roche-Campo,et al.  Ventilator-associated pneumonia by methicillin-susceptible Staphylococcus aureus: do minimum inhibitory concentrations to vancomycin and daptomycin matter? , 2017, European Journal of Clinical Microbiology & Infectious Diseases.

[8]  Peggy Cruse,et al.  Management of Adults With Hospital-acquired and Ventilator-associated Pneumonia: 2016 Clinical Practice Guidelines by the Infectious Diseases Society of America and the American Thoracic Society. , 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[9]  J. Riera,et al.  Intratracheal Administration of Antimicrobial Agents in Mechanically Ventilated Adults: An International Survey on Delivery Practices and Safety , 2016, Respiratory Care.

[10]  A. Dalhoff Pharmacokinetics and Pharmacodynamics of Aerosolized Antibacterial Agents in Chronically Infected Cystic Fibrosis Patients , 2014, Clinical Microbiology Reviews.

[11]  G. Smaldone,et al.  Reduction of bacterial resistance with inhaled antibiotics in the intensive care unit. , 2014, American journal of respiratory and critical care medicine.

[12]  Q. Lu,et al.  Aerosolized Antibiotics for Ventilator-associated Pneumonia: Lessons from Experimental Studies , 2012, Anesthesiology.

[13]  Q. Lu,et al.  Efficacy of High-dose Nebulized Colistin in Ventilator-associated Pneumonia Caused by Multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii , 2012, Anesthesiology.

[14]  Q. Lu,et al.  Nebulized ceftazidime and amikacin in ventilator-associated pneumonia caused by Pseudomonas aeruginosa. , 2011, American journal of respiratory and critical care medicine.

[15]  S. Choi,et al.  Relationship between the MIC of vancomycin and clinical outcome in patients with MRSA nosocomial pneumonia , 2011, Intensive Care Medicine.

[16]  C. Marquette,et al.  Nebulized and intravenous colistin in experimental pneumonia caused by Pseudomonas aeruginosa , 2010, Intensive Care Medicine.

[17]  Elizabeth M. Wells,et al.  The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid , 2010, Current medical research and opinion.

[18]  B. Murphy,et al.  Aerosolized vancomycin for the treatment of MRSA after lung transplantation , 2010, Respirology.

[19]  C. Marquette,et al.  Nebulized ceftazidime in experimental pneumonia caused by partially resistant Pseudomonas aeruginosa , 2009, Intensive Care Medicine.

[20]  D. Baram,et al.  Aerosolized antibiotics and ventilator-associated tracheobronchitis in the intensive care unit* , 2008, Critical care medicine.

[21]  Jerome J. Schentag,et al.  Interpretation of Antibiotic Concentration Ratios Measured in Epithelial Lining Fluid , 2007, Antimicrobial Agents and Chemotherapy.

[22]  A. S. Navarro,et al.  Pulmonary versus Systemic Delivery of Antibiotics: Comparison of Vancomycin Dispositions in the Isolated Rat Lung , 2007, Antimicrobial Agents and Chemotherapy.

[23]  R. Wunderink,et al.  Methicillin-Resistant S. aureus Ventilator-Associated Pneumonia: Strategies to Prevent and Treat. , 2006, Seminars in respiratory and critical care medicine.

[24]  M. Rybak,et al.  Epidemiology, treatment, and outcomes of nosocomial bacteremic Staphylococcus aureus pneumonia. , 2005, Chest.

[25]  R. Wunderink,et al.  Clinical cure and survival in Gram-positive ventilator-associated pneumonia: retrospective analysis of two double-blind studies comparing linezolid with vancomycin , 2004, Intensive Care Medicine.

[26]  R. Wunderink,et al.  Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. , 2003, Chest.

[27]  Jerome J. Schentag,et al.  The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. , 2002, The Journal of antimicrobial chemotherapy.

[28]  C. Marquette,et al.  Lung deposition and efficiency of nebulized amikacin during Escherichia coli pneumonia in ventilated piglets. , 2002, American journal of respiratory and critical care medicine.

[29]  C. Marquette,et al.  Influence of Lung Aeration on Pulmonary Concentrations of Nebulized and Intravenous Amikacin in Ventilated Piglets with Severe Bronchopneumonia , 2002, Anesthesiology.

[30]  C. Marquette,et al.  Lung tissue concentrations of nebulized amikacin during mechanical ventilation in piglets with healthy lungs. , 2002, American journal of respiratory and critical care medicine.

[31]  R. Glenny,et al.  Regional ventilation-perfusion distribution is more uniform in the prone position. , 2000, Journal of applied physiology.

[32]  T. Fabian,et al.  Treatment of gram-positive nosocomial pneumonia. Prospective randomized comparison of quinupristin/dalfopristin versus vancomycin. Nosocomial Pneumonia Group. , 2000, American journal of respiratory and critical care medicine.

[33]  F. Baquero,et al.  Aerosolized vancomycin for the treatment of methicillin‐resistant Staphylococcus aureus infection in cystic fibrosis , 1998 .

[34]  E. Concia,et al.  Penetration of vancomycin into human lung tissue. , 1996, The Journal of antimicrobial chemotherapy.

[35]  K. Chida,et al.  [Effect of inhaled vancomycin hydrochloride on elimination of methicillin-resistant Staphylococcus aureus]. , 1995, Nihon Kyobu Shikkan Gakkai zasshi.

[36]  R. Farinotti,et al.  Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients , 1993, Antimicrobial Agents and Chemotherapy.

[37]  L. Lutwick,et al.  Aerosolized Vancomycin Therapy Facilitating Nursing Home Placement , 1992, The Annals of pharmacotherapy.

[38]  J. Jones,et al.  Solute permeability of the alveolar capillary barrier. , 1987, Thorax.

[39]  J. Brody,et al.  Binding of Charged Ferritin to Alveolar Wall Components and Charge Selectivity of Macromolecular Transport in Permeability Pulmonary Edema in Rats , 1984, Circulation research.

[40]  E. Dahlberg Estimation of the blood contamination of tissue extracts. , 1983, Analytical biochemistry.

[41]  Petr Solich,et al.  Modern methods for vancomycin determination in biological fluids by methods based on high-performance liquid chromatography--A review. , 2016, Journal of separation science.

[42]  B. Bruguerolle,et al.  Vancomycin: a review of population pharmacokinetic analyses. , 2012, Clinical pharmacokinetics.

[43]  M. Rybak,et al.  The pharmacokinetic and pharmacodynamic properties of vancomycin. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[44]  R. Weibley,et al.  Aerosolized vancomycin for treatment of airway colonization by methicillin-resistant Staphylococcus aureus. , 1990, The Pediatric infectious disease journal.

[45]  S. Reiland Growth and skeletal development of the pig. , 1978, Acta radiologica. Supplementum.